170 related articles for article (PubMed ID: 23591180)
21. [Detection of uropathies in enuresis in children].
Podesta E; Buffa P; di Rovasenda E; Dodero P; Ferretti S; Scarsi P; Morán Penco J
An Esp Pediatr; 1984 Apr; 20(6):597-603. PubMed ID: 6742636
[TBL] [Abstract][Full Text] [Related]
22. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy.
Liu HT; Lin H; Kuo HC
Neurourol Urodyn; 2011 Nov; 30(8):1525-9. PubMed ID: 21826717
[TBL] [Abstract][Full Text] [Related]
23. Unsuccessful outcomes after posterior urethroplasty: definition, diagnosis, and treatment.
Koraitim MM
Urology; 2012 May; 79(5):1168-73. PubMed ID: 22449452
[TBL] [Abstract][Full Text] [Related]
24. Trospium chloride treatment of overactive bladder.
Biastre K; Burnakis T
Ann Pharmacother; 2009 Feb; 43(2):283-95. PubMed ID: 19193592
[TBL] [Abstract][Full Text] [Related]
25. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence.
Cartwright R; Srikrishna S; Cardozo L; Robinson D
BJU Int; 2011 Jan; 107(1):70-6. PubMed ID: 20626389
[TBL] [Abstract][Full Text] [Related]
26. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
Garely AD; Lucente V; Vapnek J; Smith N
Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
[TBL] [Abstract][Full Text] [Related]
27. Solifenacin succinate for the treatment of symptoms of overactive bladder.
Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R
Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299
[TBL] [Abstract][Full Text] [Related]
28. Boys with posterior urethral valves: outcome concerning renal function, bladder function and paternity at ages 31 to 44 years.
Holmdahl G; Sillén U
J Urol; 2005 Sep; 174(3):1031-4; discussion 1034. PubMed ID: 16094041
[TBL] [Abstract][Full Text] [Related]
29. Muscarinic receptor antagonists for overactive bladder.
Abrams P; Andersson KE
BJU Int; 2007 Nov; 100(5):987-1006. PubMed ID: 17922784
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of boys with daytime incontinence by combined cystourethroscopy, voiding cystourethrography and urodynamics.
Winck-Flyvholm L; Damgaard Pedersen K; Hildorf S; Thorup J
Scand J Urol; 2021 Jun; 55(3):249-256. PubMed ID: 33377406
[No Abstract] [Full Text] [Related]
31. Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study.
Alloussi S; Mürtz G; Braun R; Gerhardt U; Heinrich M; Hellmis E; Horn W; Marschall-Kehrel D; Niklas K; Raabe M; Rössler T; Seibt B; Siemer S; Schultz-Lampel D; Walter H; Wiedeking B; Alloussi S; Bock P; Strugala G; Madersbacher H
BJU Int; 2010 Aug; 106(4):550-6. PubMed ID: 20002668
[TBL] [Abstract][Full Text] [Related]
32. Tolterodine for the treatment of urge urinary incontinence.
Elterman DS; Chughtai B; Kaplan SA; Barkin J
Expert Opin Pharmacother; 2013 Oct; 14(14):1987-91. PubMed ID: 23885788
[TBL] [Abstract][Full Text] [Related]
33. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
34. Long-term Impacts of Concurrent Posterior Urethral Valve Ablation and Bladder Neck Incision on Urinary Continence and Ejaculation.
Keihani S; Kajbafzadeh AM; Kameli SM; Abbasioun R
Urology; 2017 Jan; 99():278-280. PubMed ID: 27720773
[TBL] [Abstract][Full Text] [Related]
35. The changes of urethral morphology recognized in voiding cystourethrography after endoscopic transurethral incision for posterior urethral valve in boys with intractable daytime urinary incontinence and nocturnal enuresis.
Hyuga T; Nakamura S; Kawai S; Kubo T; Furukawa R; Aihara T; Mieno M; Nakai H
World J Urol; 2017 Oct; 35(10):1611-1616. PubMed ID: 28247065
[TBL] [Abstract][Full Text] [Related]
36. Long-term follow-up after transurethral treatment of infravesical obstruction in boys.
Kieft JH; Hennus PM; Hoenjet E; Rynja SP; De Jong TP; Bosch JL; De Kort LM
Urology; 2014 May; 83(5):1155-60. PubMed ID: 24548707
[TBL] [Abstract][Full Text] [Related]
37. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.
Kubota Y; Kojima Y; Shibata Y; Imura M; Kohri K; Sasaki S
Neurourol Urodyn; 2011 Sep; 30(7):1309-14. PubMed ID: 21560155
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of overactive urinary bladder with imperative urinary incontinence in women].
Neĭmark AI; Riapolova MV; Mel'nik MA
Urologiia; 2010; (2):36-8. PubMed ID: 20967993
[TBL] [Abstract][Full Text] [Related]
40. Urodynamic findings in boys with posterior urethral valves after treatment with primary valve ablation or vesicostomy and delayed ablation.
Podestá ML; Ruarte A; Gargiulo C; Medel R; Castera R
J Urol; 2000 Jul; 164(1):139-44. PubMed ID: 10840447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
